Profile: Gilead Sciences, Inc. (GILD.O)

Gilead Sciences, Inc. (Gilead), incorporated on June 22, 1987, is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead’s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC’s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.

Truvada

Truvada (emtricitabine and tenofovir disoproxil fumarate) is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus (HIV) infection in adults. It is a fixed dose combination of the anti-HIV medications, Viread (tenofovir disoproxil fumarate), and Emtriva (emtricitabine).

Atripla

Atripla (efavirenz 600 milligram (mg)/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) is an oral formulation dosed once a day for the treatment of HIV infection in adults. Atripla is the first once daily single tablet regimen for HIV intended as a stand alone therapy or in combination with other antiretrovirals. It is a fixed dose combination of the anti-HIV medications, Viread and Emtriva, and Bristol Myers-Squibb Company’s non-nucleoside reverse transcriptase inhibitor, Sustiva (efavirenz).

Viread

Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. In December 31, 2008, the Company marketed Viread for the treatment of chronic hepatitis B in the United States, the European Union, and other countries, including Canada and Turkey.

Emtriva

Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. In the United States and Europe, Emtriva is used as part of combination therapy to treat HIV infection in children.

Hepsera

Hepsera (adefovir dipivoxil) is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. It commercializes Hepsera for the treatment of hepatitis B in Asia, Latin America, and certain other territories to GlaxoSmithKline Inc. (GSK).

AmBisome

AmBisome (amphotericin B liposome for injection) is a liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. The Company’s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand.

Letairis

Letairis (ambrisentan) is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Letairis is available only through a special restricted distribution program called the Letairis Education and Access Program (LEAP). Only prescribers and pharmacies registered with LEAP may prescribe, sell and distribute

Letairis.

Vistide

Vistide (cidofovir injection) is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. The Company sell Vistide in the United States through the wholesale channel and in 25 countries outside the United States.

Flolan

Flolan (epoprostenol sodium) is an injected medication for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in New York Heart Association Class III and Class IV patients who do not respond adequately to conventional therapy. Flolan is distributed in the United States through a specialty pharmacy.

Tamiflu

Tamiflu (oseltamivir phosphate) is an oral antiviral available in capsule form for the treatment and prevention of influenza A and B. Tamiflu is for the treatment of influenza in children and adults in more than 60 countries, including the United States, Japan and the European Union. Gilead developed Tamiflu with F. Hoffmann-La Roche Ltd.

Macugen

Macugen (pegaptanib sodium injection) is an intravitreal injection of an anti-angiogenic oligonucleotide for the treatment of neovascular age-related macular degeneration. Macugen was developed by OSI Pharmaceuticals, Inc. (OSI) using technology licensed from the Company and is promoted in the United States by OSI.

The Company competes with Abbott Laboratories, Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Pfizer Inc., Hoffmann-La Roche Inc., Johnson & Johnson., Enzon Pharmaceuticals, Inc, Zeneus Pharma Ltd, Three Rivers Pharmaceuticals, LLC, Genpharma, S.A, Bristol Myers-Squibb Company, Novartis Pharmaceuticals Corporation, GlaxoSmithKline Inc., Shire Pharmaceuticals Group PLC, Schering Plough Corporation, Actelion Pharmaceuticals US, Inc., United Therapeutics Corporation, and Novarti, Genentech, Inc.